PNRI-299

PNRI-299 is a selective AP-1 transcription inhibitor with an IC50 of 20 uM. PNRI-299 is a selective APE/Ref-1 inhibitor. PNRI-299 has no effect on NF-κB transcription or thioredoxin (up to 200 uM) . PNRI-299 significantly reduces airway eosinophil infiltration, mucus hypersecretion, edema, and IL-4 levels in a mouse asthma model[1][2][3].

Product Specifications

CAS Number

[550368-41-7]

UNSPSC

12352005

Target

Interleukin Related

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/PNRI-299.html

Solubility

10 mM in DMSO

Smiles

O=C1N2N(C(C(NCC3=CC=CC=C3)=O)=CC(C2)=O)C(N1C4=CC(C#N)=CC=C4)=O

Molecular Formula

C21H15N5O4

Molecular Weight

401.37

References & Citations

[1]Nguyen C, et al. Chemogenomic identification of Ref-1/AP-1 as a therapeutic target for asthma. Proc Natl Acad Sci U S A. 2003 Feb 4;100 (3) :1169-73.|[2]Souza DG, et al. NF-kappaB plays a major role during the systemic and local acute inflammatory response following intestinal reperfusion injury. Br J Pharmacol. 2005 May;145 (2) :246-54.|[3]Sun Yang, et al. Apurinic/apyrimidinic endonuclease/redox effector factor-1 (APE/Ref-1) : a unique target for the prevention and treatment of human melanoma. Antioxid Redox Signal. 2009 Mar;11 (3) :639-50.